During the week of August 24–30, 2026, the global medical device and MedTech industry saw prominent movements toward integrating AI into existing medical devices, alongside new product launches and capital investments in the cardiovascular and interventional sectors.
At the FDA, Abbott received De Novo authorization for its simultaneous continuous glucose and ketone monitoring device, while Tempus obtained 510(k) clearance for an AI medical device that detects signs of pulmonary hypertension from standard 12-lead ECGs.
Among Japanese companies, PENTAX Medical expanded its partnership with MAGENTIQ EYE globally in the field of AI-assisted colonoscopy. Meanwhile, Fujifilm launched a new system that overlays 3D images and ultrasound information onto endoscopic video feeds.
1. FDA Updates Consensus Standards Recognition List for Medical Devices ("Recognition List #66")
Publication Date: August 24, 2026
The FDA has updated its FDA Recognized Consensus Standards, which can be used to support declarations of conformity in premarket submissions for medical devices.
Recognition List #66 includes the addition of new standards as well as the revision and replacement of existing ones.
For manufacturers pursuing US submissions such as 510(k), De Novo, or PMA, it is essential to check the standards and versions currently recognized by the FDA when planning testing strategies.
Official Source: FDA: Federal Register Documents - Recognized Consensus Standards
2. FDA Grants De Novo Authorization for the World's First Wearable to Simultaneously Continuously Measure Glucose and Ketones
Publication Date: August 25, 2026
The FDA has granted De Novo authorization to Abbott’s Libre Duo 10 Day Continuous Dual Glucose Ketone Monitoring System.
Intended for diabetes patients aged 2 years and older, a single wearable sensor continuously measures both glucose and ketones every minute.
According to the FDA, this is the first wearable in the U.S. to continuously measure ketones and the world's first product to continuously monitor both glucose and ketones.
This product is attracting attention as a milestone demonstrating the evolution of CGMs from simple blood glucose meters into platforms that constantly monitor multiple biomarkers.
Official Information: FDA: FDA Authorizes First Wearable Device That Continuously Monitors Both Ketone Levels and Blood Sugar
3. Tempus Receives FDA Clearance for AI Medical Device to Detect Signs of Pulmonary Hypertension from 12-Lead ECG
Publication Date: August 24, 2026
Tempus AI's ECG-PH has obtained FDA 510(k) clearance.
This software uses AI to analyze routine 12-lead electrocardiogram (ECG) data to detect signs associated with pulmonary hypertension.
For Tempus, this is its third FDA-cleared cardiovascular AI product, following previous AI tools designed to detect atrial fibrillation and low ejection fraction.
Rather than introducing new, dedicated testing equipment, this approach expands diagnostic support capabilities by adding AI analysis to existing ECG data, drawing attention as a business model combining existing medical devices with SaMD.
Official Source: Tempus: Tempus Receives FDA Clearance for AI Product Intended to Detect Signs of Pulmonary Hypertension
4. Abbott's Next-Generation Left Atrial Appendage Closure Device "Amulet 360" Receives CE Mark
Publication Date: August 27, 2026
Abbott has announced that its next-generation left atrial appendage closure device, Amulet 360, aimed at reducing the risk of stroke in patients with atrial fibrillation, has received CE Mark approval.
The design has been updated from the conventional Amulet device, improving left atrial appendage conformability and sealing performance.
Competition in the left atrial appendage closure market continues—such as with Boston Scientific's WATCHMAN series—and product competition among major manufacturers in the structural heart disease sector is expected to intensify further.
Official Source: Abbott: Next-generation Amulet 360 receives CE Mark
5. PENTAX Medical Expands Global Partnership with AI Colonoscopy Pioneer MAGENTIQ EYE
Publication Date: August 26, 2026
PENTAX Medical, a HOYA Group company, has announced an expansion of its partnership with Israel-based MAGENTIQ EYE in the field of AI-powered endoscopy.
The collaboration, which was previously focused primarily on the United States, will now expand to EMEA, JAPAC, and LATAM.
By integrating the "MAGENTIQ-COLO" AI colonoscopy system with PENTAX Medical’s INSPIRA and IMAGINA video processors, the partnership supports real-time polyp detection and other advanced clinical applications.
This model—where an endoscope manufacturer teams up with an independent AI company to add AI capabilities to existing endoscopic platforms and roll them out globally—signals that the commercialization of AI in gastrointestinal endoscopy is entering its next phase.
Official Source: PENTAX Medical: Expanded Global Partnership with MAGENTIQ EYE
6. Fujifilm Launches "SYNAPSE VINCENT Eye," Overlaying 3D and Ultrasound Images onto Endoscopic Video
Publication Date: August 27, 2026
Fujifilm has launched the "SYNAPSE VINCENT Eye" surgical image tracking and overlay system in Japan.
The system is equipped with features such as a "Linked Viewer," which automatically rotates 3D images created from preoperative CT or MRI scans to match the orientation of the liver in the endoscopic video, and "Ultrasound Flag AR," which overlays intraoperative ultrasound images onto the endoscopic video.
In laparoscopic and robot-assisted surgeries, it supports surgeons by integrating preoperative images, endoscopic images, and intraoperative ultrasound.
This serves as an example of how diagnostic imaging technology is expanding beyond mere image display into utilization for real-time surgical navigation.
Official Source: Fujifilm: Surgical Image Tracking and Overlay System "SYNAPSE VINCENT Eye"
7. Philips and Imricor Commercialize "Interventional MR Lab" for Cardiac Catheterization Procedures Inside MRI
Publication Date: August 27, 2026
Philips and Imricor have announced the commercial rollout of the Interventional MR Lab for performing cardiac interventions in a 1.5T MRI environment.
The solution integrates Philips' MRI systems with Imricor's MR-compatible mapping systems and EP catheters.
This aims to enable procedures to be performed while monitoring cardiac anatomy, catheter locations, and post-ablation tissue changes under MRI guidance.
Unlike conventional X-ray fluoroscopy commonly used in current electrophysiology procedures, this initiative is drawing attention as an effort to expand MRI from a "diagnostic device" into a "therapeutic navigation platform."
Official Source: Philips: Philips and Imricor launch cardiac Interventional MR Lab solution
8. Philips Secures Up to $33.7 Million for AI and Robot-Assisted Remote Stroke Treatment Development
Publication Date: August 26, 2026
Philips has been selected for an R&D project backed by the U.S. Advanced Research Projects Agency for Health (ARPA-H), receiving up to $33.7 million in funding.
In collaboration with institutions such as Johns Hopkins University and Boston University, Philips will develop AI- and robotics-enabled endovascular treatment technologies for stroke.
The initiative aims to expand access to advanced endovascular treatments through remote support and automation technologies, even in regions where specialists are not permanently stationed.
By envisioning the integration of image-guided therapy systems, robotics, AI, and smart devices into a unified workflow, this development demonstrates that the competitive landscape of medical robotics is expanding into remote and semi-automated interventions.
Official Source: Philips: Philips selected for ARPA-H program to advance AI-enabled robotic stroke care
9. Kardium Invests CAD 125 Million in Manufacturing Expansion for PFA System
Publication Date: August 27, 2026
Canada-based Kardium is making a CAD 125 million capital investment in manufacturing facilities to expand the production capacity of its Globe Pulsed Field System for atrial fibrillation treatment.
The Government of Canada is supporting this project with up to CAD 31.25 million in funding.
According to government announcements, the plan is to scale up production capacity from approximately 500 units per year to a scale of 30,000 units.
As Pulsed Field Ablation (PFA) is a market where major companies such as Boston Scientific, Medtronic, and Johnson & Johnson are also focusing their efforts, Kardium's large-scale manufacturing expansion is seen as a strategic move anticipating the future growth of the PFA market.
Official Source: Kardium: Funding to expand manufacturing of the Globe Pulsed Field System
10. Boston Scientific Hit by Cyberattack, Causing Global Disruption to Manufacturing, Order, and Shipping Systems
Date of Occurrence: August 25, 2026 / Updated: August 29
On August 25, Boston Scientific confirmed a cyberattack targeting some of its IT systems.
Due to this incident, global disruptions occurred in certain systems related to manufacturing, order processing, and product shipping.
As of August 29, no impact on cloud-based systems has been identified, and the disruption is reportedly limited primarily to certain on-premises environments.
Cybersecurity in the medical device industry has become a management risk that directly impacts not only the safety of the products themselves, but also the manufacturing, logistics, and supply continuity of the manufacturer.
Official Information: Boston Scientific：Update on Recent Cybersecurity Incident
Summary
While the movement to add AI features to existing medical devices is expanding—such as Tempus's ECG analysis AI and PENTAX Medical's AI endoscopy—technologies that utilize image information for real-time treatment support are also progressing, exemplified by Fujifilm's "SYNAPSE VINCENT Eye" and Philips' Interventional MR Lab.
In addition, active investment and product development continue in the interventional cardiology field, such as Abbott's next-generation left atrial appendage closure device and Kardium's expansion of PFA manufacturing capacity.
Boston Scientific's cyberattack has once again demonstrated to medical device manufacturers that cybersecurity is not merely an issue in product development, but a critical challenge for business continuity, encompassing manufacturing, logistics, and stable supply.